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Summary Methylene dimethane sulphonate (MDMS), the first member of the homologous series of
dimethane sulphonic acid esters, was administered to 19 patients with advanced epithelial ovarian cancer. All
patients had received prior chemotherapy and in addition 3 had received prior radiotherapy. MDMS was
given as an i.v. bolus injection at a dose of 125mgm-2 and repeated in a q35 day schedule. Ten patients
received only one course, six two courses, two three courses and one four courses. The major toxicity was
thrombocytopenia which was cumulative. Serious neutropenia did not occur and no infective episodes
requiring i.v. antibiotics were seen. Seven patients experienced hair loss and four nausea and vomiting. Sixteen
patients were evaluable for response but no objective remissions were seen although three patients had stable
disease lasting at least 8 weeks. MDMS is therefore not recommended for further trial in epithelial ovarian
carcinoma.
Some 70% of ovarian cancer patients present with advanced
disease. Chemotherapy can induce remissions in 30-60% of
these patients (Young et al., 1974) but the majority will
relapse and die from their disease. Although combination
chemotherapy incorporating cis-platin can achieve somewhat
higher response rates than single agents there is little evi-
dence from randomised studies that this is translated into a
major improvement in survival (Bolis et al., 1987; Sturgeon
et al., 1982; Vogl et al., 1983). There is therefore a need for
new active agents in this condition.
Methylene dimethane sulphonate (MDMS) is the first
member (Cn= 1) of a homologous series of dimethane
sulphonic acid esters of general formula
CH3SO20.(CH2)n.020S3HC (Figure 1). Busulphan, the
fourth member of the series is widely used in the manage-
ment of chronic myeloid leukaemia. MDMS is of interest
because its small molecular size allows access to alkylating
sites not available to other agents. In particular it is able to
interact with the hydrogen bonds linking DNA strands thus
producing interstrand crosslinks (Bedford & Fox, 1982). In
pre-clinical testing MDMS was active in the rat Yoshida and
Walker sarcoma systems (Fox, 1969,1979). In the phase I
trial of MDMS the dose limiting toxicity was thrombocyto-
penia (Smith et al., 1987) and some evidence of activity was
seen in one patient with adenocarcinoma of the lung. Since
alkylating agents are amongst the most active drugs in
ovarian cancer MDMS was therefore proposed for testing in
this disease.
assessment, a WHO performance status of 0-2, a life expec-
tancy of at least 3 months and documented disease progres-
sion in the previous four weeks. Patients with a WBC
<3x 10l 1-, platelet count <lOOx l091-1, bilirubin
>25pmolI -1, creatinine > 150 umol I -1, prior chemotherapy
or radiotherapy in the previous 4 weeks (6 weeks for
mitomycin C and the nitrosoureas), CNS involvement, sub-
acute bowel obstruction or concurrent malignancies at other
sites were excluded.
Patients gave informed consent according to the practice
of participating institutions and the protocol was accepted
by the CRC protocol review committee and local ethical
committees.
Pre-treatment investigations included full blood count,
biochemical profile, liver function tests, chest X-ray and CT
scan or ultrasound scan of the abdomen where indicated.
Patients were seen 3 weeks after treatment for a nadir blood
count and radiological investigations were repeated after 2
cycles unless there was clear evidence of progression.
MDMS was given as a bolus i.v. injection at a dose of
125 mgm2. Courses were repeated on day 35 but delayed
by up to 4 weeks if full haematological recovery (platelet
count > I00 x 1091-1, WBC >3 x 1091-1) had not occurred.
Dose modifications were made as follows:
WBC nadir
x 1091-'
> 1.0
<1.0
Patients and methods
Patients with epithelial ovarian cancer whose disease had
progressed following treatment with conventional chemother-
apy were eligible for the study. All patients were required to
have evaluable disease either by clinical or radiological
1-OSO2CH3
CH2
OSt2CH3
Figure I Structure of MDMS
Platelet nadir
x 1091-1
and >70
50-70
or 25-49
<25
% previous dose
100%
75%
50%
off study
It was planned to give at least two cycles of MDMS prior
to reassessment but patients with clear evidence of progres-
sion after one course were considered to be treatment
failures and thus evaluable for response.
Response was assessed by standard UICC criteria and
toxicity was graded according to the WHO scale.
The trial used a two stage design to allow early termina-
tion if no responses occurred in the first 14 patients.
Results
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Twenty patients were entered into the study but one was
ineligible due to incorrect histology (mixed mullerian
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Table I Patient characteristics
Total no. of patients 19
Age, median (range) 54 (32-67)
Stage at original diagnosis II 2
III 12
IV 5
Histology well differentiated 2
moderately differentiated 4
poorly differentiated 7
undifferentiated 3
unclassified 3
Prior radiotherapy 3
Prior chemotherapy total 19
carboplatin or CDDP 19
alkylating agent 16
Prior response to chemotherapy 13
Sites of disease at start MDMS
local recurrence 17
lymph nodes 6
subcutaneous deposits 3
peritoneal metastases 4
liver 6
lung 4
ascites 5
pleural effusion I
alopecia in 7 patients (grade 1: 4 patients, grade 2: 1 patient,
grade 3: 2 patients).
No objective responses were seen during the study. Pro-
gressive disease occurred in 13 patients. Two patients had
stable disease after two courses and one after three courses
but were then withdrawn due to either a platelet nadir below
20 x 1091-1 with the previous course (1) or persistent throm-
bocytopenia (2). The remaining 3 patients were withdrawn
after one course, two due to thrombocytopenia and one to
the development of a second primary in the breast, and were
not considered eligible for response. In view of the lack of
objective remissions in sixteen evaluable patients the trial
was closed.
Discussion
This phase II trial confirmed that the dose limiting toxicity
of MDMS is thrombocytopenia. Moreover the platelet nadir
occurs at least 21 days following therapy and although
recovery was usual by week 6 in some cases platelets
remained below 100 x 1091 1 for several months. In addition
platelet toxicity appeared to be cumulative with lower more
prolonged nadirs with successive courses. Significant anaemia
Table II Haematological toxicity
Course 1 Course 2 Course 3
19 patients 6 patients 3 patients
Platelet nadir 65 (22-179) 61 (18-111) 36 (25-52)
median (range)
Time to nadir, weeks 3 (2-5) 3 (3-5) 4 (3-5)
median (range)
Time to recovery, weeks 4 (4-48+) 7 (4-10+) 9 (8-10)
median (range)
WBC nadir 2.2 (1.2-10.7) 2.2 (1.1-4.8) 2.8 (1.7-4.0)
median (range)
tumour). The characteristics of the 19 eligible patients are
shown in Table I.
Ten patients received one course of MDMS, 6 patients
two courses, 2 patients three courses and 1 patient four
courses. The reasons for discontinuing treatment were pro-
gressive disease 13 patients, early death I patient and
persistent thrombocytopenia 5 patients. Six out of 9 patients
who received two or more courses required dose reductions
and 6 patients were given blood transfusions as a result of
treatment related anaemia. Two patients required platelet
transfusions, both following the second cycle of MDMS,
when the platelet count fell below 20 x 1091-1. Platelet and
WBC nadirs according to course are shown in Table II.
There was no hepatic or renal toxicity observed during the
trial. No episodes of infection requiring i.v. antibiotics
occurred.
Non-haematological toxicity included nausea and vomiting
in 4 patients (grade 1: 3 patients, grade 3: 1 patient) and
also occurred and 6 of the 9 patients who received at least
two cycles of therapy required transfusions. Neutropenia on
the other hand was not a problem and there was no instance
during the study of a WBC nadir below 1.0 x 1091-1 and no
serious episodes of infection occurred.
MDMS was subjectively well tolerated the major side
effect being alopecia which affected 7 patients 6 of whom
had had at least two courses. In only 2 patients was a wig
required. Nausea and vomiting was mild and occurred in
only 4 patients lasting a maximum of 12h.
Although 3 patients had stable disease for periods in
excess of 8 weeks no objective remissions were seen during
the study. MDMS would therefore appear to be inactive in
patients with ovarian cancer who have received prior chemo-
therapy and cannot be recommended for further study in
this condition. Moreover the delayed platelet nadir and
cumulative nature of this toxicity would make it difficult to
incorporate MDMS in combination regimens.
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